+

PE20081346A1 - Derivados de espiroindolinona como antagonistas de mdm2 - Google Patents

Derivados de espiroindolinona como antagonistas de mdm2

Info

Publication number
PE20081346A1
PE20081346A1 PE2007001533A PE2007001533A PE20081346A1 PE 20081346 A1 PE20081346 A1 PE 20081346A1 PE 2007001533 A PE2007001533 A PE 2007001533A PE 2007001533 A PE2007001533 A PE 2007001533A PE 20081346 A1 PE20081346 A1 PE 20081346A1
Authority
PE
Peru
Prior art keywords
diona
rac
indol
chlorophenyl
cyclohexane
Prior art date
Application number
PE2007001533A
Other languages
English (en)
Inventor
Jin-Jun Liu
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38942414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081346A1 publication Critical patent/PE20081346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE ESPIROINDOLINONA DE FORMULA (Ia) O (Ib), DONDE X ES H, HALOGENO, CIANO, NITRO, ETINILO O CICLOPROPILO; Y ES HIDROGENO; R1, R2, R3 Y R4 SON H, ALQUILO, HETEROCICLO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: RAC-(1R,2S,6S)-6'-CLORO-2-(3-CLOROFENIL)-6-METOXIESPIRO[CICLOHEXANO-1,3'-[3H]INDOL]-2',4(1'H)-DIONA, RAC-(1S,2S,6R)-6'-CLORO-2-(3-CLOROFENIL)-6-(5-FLUOR-2-METIL-FENIL)ESPIRO[CICLOHEXANO-1,3'-[3H]INDOL]-2',4(1'H)-DIONA, RAC-(1R,2S,6S)-6'-CLORO-2-(3-CLOROFENIL)-6-CICLOPROPILESPIRO-[CICLOHEXANO-1,3'-[3H]INDOL]-2',4(1'H)-DIONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA FORMULACION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD ANTAGONISTA EN LAS INTERACCIONES DE LA PROTEINA MDM2 Y SON UTILES EN EL TRATAMIENTO O CONTROL DE TRASTORNOS DE PROLIFERACION CELULAR COMO EL CANCER
PE2007001533A 2006-11-09 2007-11-07 Derivados de espiroindolinona como antagonistas de mdm2 PE20081346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85803906P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
PE20081346A1 true PE20081346A1 (es) 2008-10-24

Family

ID=38942414

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001533A PE20081346A1 (es) 2006-11-09 2007-11-07 Derivados de espiroindolinona como antagonistas de mdm2

Country Status (16)

Country Link
US (1) US7638548B2 (es)
EP (1) EP2089360B1 (es)
JP (1) JP2010509260A (es)
KR (1) KR20090095563A (es)
CN (1) CN101535255A (es)
AR (1) AR063602A1 (es)
AT (1) ATE512135T1 (es)
AU (1) AU2007316740A1 (es)
CA (1) CA2668398A1 (es)
CL (1) CL2007003202A1 (es)
ES (1) ES2364784T3 (es)
IL (1) IL198319A0 (es)
MX (1) MX2009004766A (es)
PE (1) PE20081346A1 (es)
TW (1) TW200829551A (es)
WO (1) WO2008055812A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134001B2 (en) * 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
US20110269812A1 (en) * 2008-10-14 2011-11-03 Agency For Science, Technology And Research Novel benzylidene-indolinone and their medical and diagnostic uses
US20100190814A1 (en) * 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) * 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
CN104876938A (zh) * 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) * 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
MX342958B (es) 2011-03-10 2016-10-18 Daiichi Sankyo Co Ltd Derivados de diespiropirrolidina.
CN102180828A (zh) * 2011-03-31 2011-09-14 四川大学 手性吲哚啉酮螺五环骨架化合物及不对称合成
EP2707372B1 (en) 2011-05-11 2016-12-21 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
CN103992334A (zh) * 2014-05-29 2014-08-20 中国人民解放军第二军医大学 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
CN107530336B (zh) 2015-04-13 2020-09-25 第一三共株式会社 组合使用mdm2抑制剂和btk抑制剂的治疗方法
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
KR20190068544A (ko) 2016-10-17 2019-06-18 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법
US11046703B2 (en) 2018-10-08 2021-06-29 The Regents Of The University Of Michigan Small molecule MDM2 protein degraders
EP4121043A4 (en) 2020-03-19 2024-07-24 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
CN113149890B (zh) * 2021-04-27 2023-01-03 华东理工大学 合成3-螺-2-吲哚酮类化合物的方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN116354786A (zh) * 2021-12-27 2023-06-30 北京化工大学 一种碗状并苯类化合物，制备及应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
HUP9902374A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
EA014445B1 (ru) * 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives

Also Published As

Publication number Publication date
AU2007316740A1 (en) 2008-05-15
AR063602A1 (es) 2009-02-04
EP2089360B1 (en) 2011-06-08
JP2010509260A (ja) 2010-03-25
US7638548B2 (en) 2009-12-29
KR20090095563A (ko) 2009-09-09
IL198319A0 (en) 2010-02-17
TW200829551A (en) 2008-07-16
MX2009004766A (es) 2009-05-21
CN101535255A (zh) 2009-09-16
CL2007003202A1 (es) 2008-03-07
EP2089360A1 (en) 2009-08-19
ATE512135T1 (de) 2011-06-15
WO2008055812A1 (en) 2008-05-15
ES2364784T3 (es) 2011-09-14
US20080114013A1 (en) 2008-05-15
CA2668398A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
PE20081346A1 (es) Derivados de espiroindolinona como antagonistas de mdm2
PE20090279A1 (es) Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2
PE20090718A1 (es) Derivados de espiroindolinona
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
PE20120418A1 (es) DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)
PE20080059A1 (es) Quinazolinas para la inhibicion de pdk1
ATE424402T1 (de) Imidazopyridinverbindungen
CR9929A (es) Nuevos compuestos
EA201070169A1 (ru) 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
CL2008002911A1 (es) Compuestos derivados de [arilo heteroarilo]-[1-piperidinilo susutituido]metanona, antagonista del receptor ccr-2, ccr-3, ccr-5; proceso de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de la enfermedad arterial periferica oclusiva e isquemia critica de las extremidades, entre otras.
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20071138A1 (es) Derivados de pirimidina como inhibidores de quinasas
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
MY137609A (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
NI200300053A (es) Derivados del tropano utiles en terapia.
BRPI0412327A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
UY30706A1 (es) Diaril, dipiridinil y arilpiridinil derivados y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载